Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% ...

Regeneron has announced that the European Commission (EC) has approved Libtayo (cemiplimab) as a monotherapy for the treatment of adult patients with second-line recurrent or metastatic cervical ...

With a market cap of $62.4 billion, Regeneron Pharmaceuticals ... the company’s products include EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, and Kevzara. More Top Stocks Daily: Go behind ...

With a market cap of $62.4 billion, Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and ...

Sanofi and Regeneron's latecomer checkpoint inhibitor Libtayo has largely been protected from heavyweight competition in its first niche markets, but now looks set to for a toe-to-toe contest with ...

Regeneron Pharmaceuticals ... injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma ...

The PD-L1 IHC 22C3 PharmDx (Code SK006) assay is now certified for use to aid treatment decisions for patients with gastric or gastroesophageal junction adenocarcinoma.

In a report released on April 11, Salveen Richter from Goldman Sachs maintained a Buy rating on Regeneron (REGN – Research Report), with a price target of $917.00. The company’s shares closed ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...